Webinars and Events | May 24, 2023
The latest generation of prescription drugs originally developed to help people manage their type 2 diabetes, such as Ozempic®, have been causing quite a stir for patients, health professionals and benefit plans now that some have been both approved and promoted for treating obesity. The effectiveness of and demand for these newer drugs are prompting some plan sponsors that exclude anti-obesity drugs from coverage to revisit plan rules. However, there are concerns about the potentially large target patient population, as well as the increased utilization and the high cost of these drugs.
This webinar addresses the range of issues plan sponsors face related to weight-loss benefits and potential coverage of newer anti-obesity drug therapies.
Don’t have time to watch a video right now? No worries. Here is a copy of the slides from this session.
Download NowThis page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.
Don't miss out. Join 16,000 others who already get the latest insights from Segal.